#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	19336	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2332	1009.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1563	1563	C	1273	C,A	1271,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	19336	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2332	1009.3	0	HET	.	.	.	A69G	.	69	69	A	448	448	A	1212	A,G	912,297	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33458	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3939	1056.1	0	.	n	.	0	T695C	SNP	695	695	T	1218	1218	C	1190	C,A,G	1186,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33458	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3939	1056.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1860	1860	A	1334	A,G	1333,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33458	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3939	1056.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2494	2494	C	1169	C,G,T	1164,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33458	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3939	1056.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2568	2568	A	1137	A,G,C	1135,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33458	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3939	1056.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3120	3120	C	1202	C,G	1197,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2626	folP	855	855	100.0	folP.l15.c4.ctg.1	2016	162.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1266	1268	AGC	265;264;266	A,C;G;C	262,1;263;265	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3998	191.6	1	SNP	p	S91F	1	.	.	271	273	TTC	937	939	TTC	221;222;218	T;T;C,T	221;222;217,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3998	191.6	1	SNP	p	D95G	1	.	.	283	285	GGC	949	951	GGC	224;223;222	G;G,C;C,T,A,G	224;222,1;219,1,1,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6142	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3998	191.6	1	SNP	p	G95N	0	.	.	283	285	GGC	949	951	GGC	224;223;222	G;G,C;C,T,A,G	224;222,1;219,1,1,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2450	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1974	154.9	1	SNP	p	G45D	0	.	.	133	135	GGC	805	807	GGC	285;282;280	G;G,A;C,A	285;281,1;279,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1386	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1369	125.9	0	.	n	.	0	A197.	DEL	197	197	A	778	778	A	277	A	277	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5942	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	209.8	1	SNP	p	D86N	0	.	.	256	258	GAC	890	892	GAC	292;292;287	G;A,T;C,G	292;291,1;286,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5942	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	209.8	1	SNP	p	R87I	0	.	.	259	261	CGT	893	895	CGT	289;287;287	C;G;T,G,A	289;287;284,2,1	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5942	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	209.8	1	SNP	p	R87W	0	.	.	259	261	CGT	893	895	CGT	289;287;287	C;G;T,G,A	289;287;284,2,1	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5942	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	209.8	1	SNP	p	S87R	1	.	.	259	261	CGT	893	895	CGT	289;287;287	C;G;T,G,A	289;287;284,2,1	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5942	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	209.8	1	SNP	p	S88P	0	.	.	262	264	TCC	896	898	TCC	287;287;286	T,A;C;C	286,1;287;286	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5060	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3169	198.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1831	1833	GGC	269;269;266	G;G;C,A	268;268;264,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1463	1465	GCA	323;323;322	G;C;A	322;323;322	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1466	1468	ATC	320;320;315	A,C;T;C	319,1;320;315	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1478	1480	GTG	316;315;314	G;T;G,C	316;315;313,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1478	1480	GTG	316;315;314	G;T;G,C	316;315;313,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1982	1984	ACC	281;283;282	A;C;C	281;283;282	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2036	2038	GCG	270;272;268	G;C,T,G;G	270;270,1,1;268	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2036	2038	GCG	270;272;268	G;C,T,G;G	270;270,1,1;268	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2159	2161	AGC	239;238;241	A;G,T;C	239;237,1;241	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2168	2170	GGC	242;244;244	G,T;G;C	241,1;244;244	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	5068	penA	1752	1752	100.0	penA.l15.c17.ctg.1	2791	226.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2186	2188	CCG	250;254;252	C,G;C;G,A	249,1;254;250,2	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	7120	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3643	243.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1854	1856	CCG	289;290;289	C;C,A;G	289;289,1;288	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2828	porA	1146	1146	99.91	porA.l15.c17.ctg.1	2153	162.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	751	751	C	218	C,A	217,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	22;23;27	T;T;A	22;23;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	70;70;70	C,T;A;T	69,1;70;70	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	70;70;70	A;G,C;T	70;69,1;70	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	70;70;70	T;A;C	70;70;70	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	656	20.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	56.3	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	65;63;62	A;C;G	65;63;62	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	334	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	182	56.3	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	20;20;15	C,A;A;A	19,1;20;15	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	593	595	GAA	349;349;351	G,A,T;A;A,T	346,2,1;348;350,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	K120N	NONSYN	358	360	AAG	839	841	AAC	310;308;308	A,T,C;A,T;C	308,1,1;307,1;308	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	881	883	GAT	338;339;343	G,T,A;A,C;T	336,1,1;338,1;343	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1004	1006	TCA	337;336;335	T;C;A,C	337;336;334,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1133	1135	GTC	347;349;353	G;T;C	345;348;352	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1145	1147	TCT	356;356;355	T;C;T,G	356;355;354,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1463	1465	GCA	309;310;310	G,T;C;A	308,1;310;310	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	1	SNP	p	A121D	1	.	.	361	363	GAC	842	844	GAC	308;315;315	G,C;A;C,T	307,1;315;312,3	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3900	porB1b	1047	1047	99.14	porB1b.l15.c30.ctg.1	1879	256.6	1	SNP	p	D121N	0	.	.	361	363	GAC	842	844	GAC	308;315;315	G,C;A;C,T	307,1;315;312,3	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	13166	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5196	315.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1906	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1460	162.6	1	SNP	p	V57M	1	.	.	169	171	ATG	693	695	ATG	334;334;329	A;T;G,C,A	334;334;327,1,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
